Navigation Links
Study Weighs Cost, Benefit of Gene Tests Before Warfarin Rx
Date:1/20/2009

The screens resulted in better patient outcomes but at high price, researchers say

TUESDAY, Jan. 20 (HealthDay News) -- Genetic testing isn't cost-effective in guiding initial dosing of the blood thinner warfarin in patients with atrial fibrillation (a type of abnormal heart rhythm), a University of Cincinnati study finds.

Warfarin is used to prevent blood clotting in these patients. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin to suggest that doctors consider genetic testing before using the blood thinner.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," study lead investigator Dr. Mark Eckman, professor of medicine, explained in a UC news release.

"The idea behind genetic testing -- also known as pharmacogenetic-guided dosing -- is to help guide the initial, and possibly lower, dose of warfarin for patients," Eckman said. "The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

He and his colleagues analyzed the findings of three published studies and then created a model to estimate the cost-effectiveness of genetic testing.

They found that genotype-guided dosing did result in better patient outcomes but at a cost of more than $170,000 per quality-adjusted life year gained. They also found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective. The findings were published in the Jan. 20 issue of the journal Annals of Internal Medicine.

The researchers concluded that genotype-guiding dosing is cost effective if it:

  • is used for patients at high risk for hemorrhage;
  • prevents more than 32 percent of major bleeding events;
  • is available within 24 hours;
  • costs less than $200.

"This could be accomplished if testing were done in-house, at lower cost and without delays," said Eckman. Currently, most of these tests have to be sent to outside laboratories, which can lead to increased cost and treatment delays.

More information

The U.S. Agency for Healthcare Research and Quality has more about warfarin.



-- Robert Preidt



SOURCE: University of Cincinnati, news release, Jan. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study compares 2 nonsurgical treatments for reflux disease
2. Study examines racial disparities in survival among patients diagnosed with lung cancer
3. Study shows rise in antibiotic resistant pediatric head and neck infections
4. Study: Growth in research comes at a steep price
5. National Childrens Study Begins Recruiting
6. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
7. Tufts receives NIH grant to study obesity prevention in new immigrants
8. New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage
9. 2009 Most Wired Survey and Benchmarking Study Opens Today
10. Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
11. Newer Antipsychotics Pose Cardiac Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Weighs Cost, Benefit of Gene Tests Before  Warfarin Rx
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of warmer weather ... those self-conscious about a double chin, this means more anxiety than elation. The cosmetic ... “For most people, a double chin is undesirable,” Dr. Goldman said, “but it seems ...
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio and ... to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National Advisory ... propel the clinic from a small start-up to number 78 in the country based ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment Center® ... March 13-16, was a busy spot this year. Liz Solovay and Adrian Picheny, ... preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice infestations ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  BERG, a biopharmaceutical company uncovering health ... today announced that the company,s Interrogative Biology® ... data using a cold-induced model to promote ... Diabetes Center led the investigation with BERG ... of samples.  The findings were published in ...
(Date:3/27/2017)... YORK , March 27, 2017 ... colors as the NASDAQ Composite closed the trading session ... lower; and the S&P 500 was down 0.08%. US ... nine sectors finishing the day in green. Pre-market today, ... Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: ...
(Date:3/27/2017)... , March 27, 2017  Allergan plc, ... Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company ... therapies based upon tetracycline chemistry, announced that two ... treatment of moderate to severe acne met their ... once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory ...
Breaking Medicine Technology: